Omics-Based Clinical Trials Market Report 2025

The omics-based clinical trials market size has grown strongly in recent years. It will grow from $29.1 billion in 2024 to $31.71 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to the increasing number of clinical trials utilizing omics technologies, a stronger focus on translational research, rising government funding and support, expanded availability of biobanks and biospecimens, and growing awareness of the advantages offered by precision therapies.

The omics-based clinical trials market size is expected to see strong growth in the next few years. It will grow to $44.08 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to the rising demand for personalized medicine, increasing adoption of multi-omics approaches, growing prevalence of chronic and rare diseases, expanding investment in genomic research and biotechnology, and heightened focus on biomarker discovery. Major trends in the forecast period include advancements in next-generation sequencing (NGS) technologies, integration of artificial intelligence with omics platforms, innovations in bioinformatics tools, progress in proteomics and metabolomics platforms, and enhanced integration of multi-omics data.

The growing demand for personalized medicine is expected to drive the expansion of the omics-based clinical trials market in the coming years. Personalized medicine involves tailoring disease prevention, diagnosis, and treatment to the unique characteristics of each patient. This demand is increasing due to advances in genomic technologies that enable faster, more cost-effective analysis of individual genetic profiles, guiding targeted therapies. Omics-based clinical trials support personalized medicine by identifying patients’ genetic, proteomic, and metabolic profiles, allowing for more precise and effective treatment strategies. For example, in February 2023, the Personalized Medicine Coalition, a US-based professional membership organization, reported that 12 new personalized medicines were approved in 2022, accounting for roughly 34% of all newly approved therapies, marking a significant rise from previous years. Consequently, the growing adoption of personalized medicine is driving growth in the omics-based clinical trials market.

Companies in the omics-based clinical trials market are focusing on innovations such as HiFi sequencing technology to improve the accuracy, speed, and depth of multi-omics data analysis, thereby enhancing trial outcomes and personalized treatment strategies. HiFi sequencing is a next-generation sequencing (NGS) technology that produces long, highly accurate reads using circular consensus sequencing (CCS), enabling comprehensive analysis of genomes, transcriptomes, and epigenomes. For instance, in October 2024, Pacific Biosciences of California Inc., in collaboration with the Agency for Science, Technology, and Research (A\STAR) in Singapore and Macrogen Inc. in South Korea, launched a state-of-the-art genomics lab in Singapore. The facility employs advanced long-read sequencing technology to support applications such as whole genome sequencing, transcriptomics, epigenetics, and metagenomics. It also fosters collaboration between global researchers and local institutions, accelerating personalized medicine, rare disease diagnostics, and precision oncology, while providing training and shared access to high-throughput sequencing infrastructure in the Asia-Pacific region.

In June 2025, Bruker Corporation, a US-based manufacturer of scientific instruments and diagnostic tests, acquired Biocrates Life Sciences AG for an undisclosed amount. Through this acquisition, Bruker aims to strengthen its multiomics offerings by integrating Biocrates’ mass spectrometry-based metabolomics technologies, delivering standardized, reproducible, and comprehensive workflows for life sciences and clinical research. Biocrates Life Sciences AG, based in Austria, specializes in providing omics-based clinical trial solutions.

Major players in the omics-based clinical trials market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., GlaxoSmithKline Plc, Eli Lilly and Company, Novo Nordisk A/S, BioNTech SE, IQVIA Inc., Laboratory Corporation of America Holdings, ICON Public Limited Company, SGS Société Générale de Surveillance SA, Eurofins Scientific SE, Syneos Health Inc., Illumina Inc., Charles River Laboratories International Inc., Parexel International Corporation, Bruker Corporation, Fulgent Genetics Inc., Signios Biosciences, and BioAro Inc.

North America was the largest region in the omics-based clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in omics-based clinical trials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the omics-based clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Omics-based clinical trials are studies that utilize omics technologies such as genomics, proteomics, transcriptomics, metabolomics, and epigenomics to explore disease mechanisms, identify biomarkers, predict treatment responses, and personalize medical care. These trials employ high-throughput molecular data to guide patient selection, stratification, and therapy optimization, aiming to improve outcomes and minimize adverse effects through precision medicine approaches.

The primary types of omics-based clinical trials include genomics, proteomics, metabolomics, and transcriptomics. Genomics focuses on analyzing an organism’s complete DNA sequence to understand gene structure, function, and their roles in health and disease. These trials progress through phases I to IV and commonly follow study designs such as interventional studies, observational studies, and expanded access studies. They are widely applied in areas like oncology, cardiovascular medicine, neurology, infectious diseases, and metabolic disorders, and serve various end users, including pharmaceutical and biotechnology companies, academic and research institutions, contract research organizations (CROs), and hospitals and diagnostic laboratories.

The omics-based clinical trials market research report is one of a series of new reports that provides omics-based clinical trials market statistics, including the omics-based clinical trials industry's global market size, regional shares, competitors with the omics-based clinical trials market share, detailed omics-based clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the omics-based clinical trials market. This omics-based clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The omics-based clinical trials market consists of revenues earned by entities by providing services such as genomics analysis, transcriptomics profiling, proteomics studies, and metabolomics assessments. The market value includes the value of related goods sold by the service provider or included within the service offering. The omics-based clinical trials market also includes sales of next-generation sequencing (NGS) platforms, mass spectrometry instruments, microarrays, bioinformatics software, reagents, and kits. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.